CHE vs. AMED, OPCH, HSIC, QGEN, RGEN, THC, ROIV, TFX, TECH, and LEGN
Should you be buying Chemed stock or one of its competitors? The main competitors of Chemed include Amedisys (AMED), Option Care Health (OPCH), Henry Schein (HSIC), Qiagen (QGEN), Repligen (RGEN), Tenet Healthcare (THC), Roivant Sciences (ROIV), Teleflex (TFX), Bio-Techne (TECH), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Chemed (NYSE:CHE) and Amedisys (NASDAQ:AMED) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends.
95.9% of Chemed shares are held by institutional investors. Comparatively, 94.4% of Amedisys shares are held by institutional investors. 3.3% of Chemed shares are held by insiders. Comparatively, 1.8% of Amedisys shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Chemed has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, Amedisys has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
Chemed currently has a consensus price target of $681.00, indicating a potential upside of 21.25%. Amedisys has a consensus price target of $100.80, indicating a potential upside of 9.47%. Given Chemed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Chemed is more favorable than Amedisys.
Amedisys received 166 more outperform votes than Chemed when rated by MarketBeat users. However, 63.39% of users gave Chemed an outperform vote while only 58.93% of users gave Amedisys an outperform vote.
In the previous week, Amedisys had 4 more articles in the media than Chemed. MarketBeat recorded 10 mentions for Amedisys and 6 mentions for Chemed. Amedisys' average media sentiment score of 0.76 beat Chemed's score of 0.69 indicating that Amedisys is being referred to more favorably in the news media.
Chemed has higher revenue and earnings than Amedisys. Amedisys is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.
Chemed has a net margin of 12.36% compared to Amedisys' net margin of -0.91%. Chemed's return on equity of 30.52% beat Amedisys' return on equity.
Summary
Chemed beats Amedisys on 14 of the 18 factors compared between the two stocks.
Get Chemed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CHE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
